| Course | NR 546 Advanced Pharmacology: Psychopharmacology for the Psychiatric-Mental Health Nurse Practitioner |
|---|---|
| Week | 3 |
| Paper type | Medication selection rationale |
| Length | About 1,110 words, 2 pages |
| Format | APA 7 student paper |
| School | Chamberlain University |
| Program | MSN, Psychiatric-Mental Health Nurse Practitioner (PMHNP) |
| Updated | September 2026 |
Free sample paper for NR 546 Week 3
Medication Selection Rationale: Escitalopram 5 mg for a First Episode of Depression With Anxious Distress, Chosen Over Sertraline, Bupropion and Mirtazapine on Grounds Taken From This Patient
Student Name
College of Nursing, Chamberlain University
NR 546: Advanced Pharmacology: Psychopharmacology for the Psychiatric-Mental Health Nurse Practitioner
Instructor Name
Month Day, Year
Medication Selection Rationale: Escitalopram 5 mg for a First Episode of Depression With Anxious Distress, Chosen Over Sertraline, Bupropion and Mirtazapine on Grounds Taken From This Patient
The Choice
For a 41-year-old teacher in a first major depressive episode, one marked by anxious distress, I would start escitalopram 5 mg by mouth once daily for seven days, then 10 mg once daily. The target symptoms are the ones the patient named: waking at 4 a.m. and being unable to return to sleep, constant worry about work that makes lesson planning impossible, and loss of interest in running, which the patient used to do three times a week. The baseline Patient Health Questionnaire-9 (PHQ-9) score is 18 and the Generalized Anxiety Disorder-7 (GAD-7) score is 13. The rest of this rationale explains why escitalopram and not its obvious competitors.
Patient Factors That Separate the Agents
Within the newer antidepressants, differences in average efficacy are small. A network meta-analysis of 21 antidepressants found all more effective than placebo, with modest differences between agents and escitalopram among those with relatively good acceptability (Cipriani et al., 2018). Class-level efficacy therefore does little to separate the options. What separates them for this patient are six specific facts.
Anxious distress. The depression includes prominent worry and tension.
A previous activating response. At age 29, the patient took fluoxetine 20 mg for three weeks and stopped because of jitteriness and insomnia.
Weight and glucose. Body mass index is 32 and HbA1c is 6.1%, in the prediabetes range.
Irritable bowel syndrome with diarrhea, currently managed with diet and occasional loperamide.
Stated priorities. The patient named weight gain and sexual problems as the two things that would end any trial.
Other medications. Sumatriptan about twice a month for migraine and ibuprofen occasionally for back pain. No other regular medications. The patient uses an intrauterine device and is not pregnant.
Screening found no history suggesting mania or hypomania and no family history of bipolar disorder. On the Columbia Suicide Severity Rating Scale, the patient described fleeting thoughts over the past month that it might be better not to wake, without any plan, intent or earlier attempt.
The Alternatives Taken Seriously
Sertraline. Sertraline is a strong alternative with similar efficacy and good acceptability, and it would have been a reasonable first choice for many patients. What rules it out for this patient is the bowel. Sertraline is known among the selective serotonin reuptake inhibitors for a higher rate of loose stools and diarrhea, and this patient's irritable bowel syndrome is diarrhea-predominant. A drug that adds to the patient's most disruptive physical symptom in the first weeks, when benefit has not yet arrived, is likely to be stopped. Escitalopram also causes gastrointestinal effects, but less of this particular one is expected, and starting at 5 mg reduces early upset.
Bupropion. Bupropion has real advantages here: it is weight-neutral and rarely causes sexual dysfunction (Serretti & Chiesa, 2009), which matches both of the patient's stated priorities. It is not chosen for two reasons from this case. First, the depression includes anxious distress. A pooled analysis of 10 trials found a modest advantage for selective serotonin reuptake inhibitors over bupropion in patients with high levels of anxiety (Papakostas et al., 2008). Second, the patient's previous experience of jitteriness and insomnia on an activating agent suggests sensitivity to exactly the effects bupropion is most likely to cause. Bupropion remains the natural choice for augmentation or a switch if sexual dysfunction becomes a problem.
Mirtazapine. Mirtazapine would help sleep and has low rates of sexual dysfunction. It is ruled out because histamine blockade commonly increases appetite and weight, in a patient whose weight already sits in the obese range and whose glucose is in the prediabetic band. The sedation that could be an advantage for early-morning waking does not outweigh a likely rise in weight and glucose in a patient who has named weight gain as a reason to stop.
Why Escitalopram Fits
Escitalopram suits the anxious component, having evidence in both depression and generalized anxiety. It has minimal effect on weight in the short term, few interactions with the patient's other medications and a simple once-daily dose. It is less activating than fluoxetine, whose long half-life and early jitteriness the patient remembers. It does carry a risk of sexual dysfunction, which will be discussed openly at the start, with a plan to address it if it arises rather than a promise that it will not.
Cost and access also favor it. Escitalopram is available as a low-cost generic, which matters for a teacher paying a deductible, and it comes in a 5 mg tablet, which makes the planned lower first week simple. Its once-daily dosing fits a working day that begins before 7 a.m. None of these would decide the choice alone, but a drug the patient can obtain and take easily is more likely to get a fair trial.
Starting Dose and Its Reason
The usual starting dose for escitalopram in adults is 10 mg daily. I would start at 5 mg for the first week because of this patient's history of activation with fluoxetine and irritable bowel symptoms. A lower first week reduces early nausea, loose stools and restlessness, which are the effects most likely to end the trial before benefit appears. The increase to 10 mg at day 8 brings the patient to a usual therapeutic dose within the time benefit would be expected to begin. The patient has no cardiac history and takes no other drugs that prolong the QT interval, and at age 41 no dose limit for age applies.
What Would Change the Decision
Several findings would change the choice before or after starting. A history of hypomania uncovered on further questioning would change the whole approach, since an antidepressant alone can precipitate mania in bipolar disorder. Pregnancy planning would lead to a discussion of risks and benefits, though escitalopram would still be an option. After starting, intolerable diarrhea despite the lower dose would favor a switch to bupropion; sexual dysfunction that the patient finds unacceptable would favor adding or switching to bupropion; and no improvement at all by four weeks at 10 mg would prompt a review of the dose, adherence and diagnosis. Any increase in suicidal thinking, or the emergence of intent or a plan, would require immediate reassessment of safety regardless of the medication plan.
References
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., Egger, M., Takeshima, N., Hayasaka, Y., Imai, H., Shinohara, K., Tajika, A., Ioannidis, J. P. A., & Geddes, J. R. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. The Lancet, 391(10128), 1357-1366. https://doi.org/10.1016/S0140-6736(17)32802-7
Papakostas, G. I., Stahl, S. M., Krishen, A., Seifert, C. A., Tucker, V. L., Goodale, E. P., & Fava, M. (2008). Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): A pooled analysis of 10 studies. Journal of Clinical Psychiatry, 69(8), 1287-1292. https://doi.org/10.4088/JCP.v69n0812
Serretti, A., & Chiesa, A. (2009). Treatment-emergent sexual dysfunction related to antidepressants: A meta-analysis. Journal of Clinical Psychopharmacology, 29(3), 259-266. https://doi.org/10.1097/JCP.0b013e3181a5233f
What the NR 546 Week 3 assignment asks for
For the third week, the task is to select a psychotropic agent for a patient and defend the choice. The prompt typically asks for the chosen medication and target symptoms, relevant patient factors, the rationale, alternatives considered, the starting dose and evidence. State the agent and the symptoms it targets at the top. Collect the patient factors that actually separate agents: prior response or failure, comorbidities, other medications, tolerability concerns and the patient's own priorities. Take one or two genuine competitors seriously, saying what would favor each and what rules it out for this person. Justify the starting dose with patient reasons. Close with the findings that would change your decision, including safety concerns. Comparative trial evidence, cited in APA 7, belongs beside the claims it supports.
Inside the NR 546 Week 3 example
The rationale opens with escitalopram 5 mg for seven days then 10 mg, and the target symptoms in the patient's words with baseline PHQ-9 and GAD-7 scores. A section notes that efficacy differences between newer antidepressants are small and lists six patient factors, plus negative bipolar screening and passive death wishes. The alternatives section rules out sertraline for its bowel effects, bupropion for anxious distress, supported by a pooled analysis, and a prior activating reaction, and mirtazapine for weight gain. A section explains why escitalopram fits, including cost and a 5 mg tablet. The dose section justifies the lower start. The closing section lists findings that would change the choice before or after starting, with safety first.
Where the points sit in the NR 546 Week 3 rubric
Selection rationales are generally judged on an appropriate choice, thorough use of patient factors, genuine consideration of alternatives, a justified starting dose and supporting evidence. A rationale that spends its length on why the obvious competitor was not chosen shows the reasoning instructors read for. Patient-specific reasons, such as a bowel condition or a past reaction, carry far more weight than class-level efficacy statements. A starting dose justified by this patient's sensitivities shows individualized prescribing. Naming what would change the decision, including safety triggers, demonstrates clinical judgment. Screening for bipolar disorder and suicide risk before choosing shows safe practice. Current comparative evidence, cited accurately in APA 7, completes a strong rationale.
NR 546 Week 3 help: mistakes that cost points
Rationales often recommend a drug because it is first line and stop there, which says nothing about this patient. Give patient reasons. Another weakness is dismissing alternatives in a sentence; take at least one seriously and explain what rules it out. Some students start at the standard dose without considering whether this patient needs a lower start. Avoid relying on small efficacy differences between agents in the same class. Include safety screening, since an antidepressant alone is inappropriate in bipolar disorder. Do not promise the patient will avoid a side effect; say how you will manage it if it appears. Keep the patient's priorities visible, because a drug the patient will not take is not the right choice however good its evidence.
Get a NR 546 Week 3 example written to your instructions
Send the Week 3 instructions and the case your section supplies, and a custom example is written as a rationale for that patient and returned inside 24 to 48 hours. The first one is free. Any prescribing you do at your own site stays yours.
More NR 546 papers and PMHNP samples
- NR 546 Week 1: Antidepressant Timing Discussion
- NR 546 Week 2: Receptor Mechanism Write-Up
- NR 546 Week 4: Titration and Monitoring Plan
- NR 546 Week 5: Case Analysis
- NR 546 Week 6: Adverse Effect Brief
- NR 546 Week 7: Medication Education Handout
- NR 546 Week 8: Psychopharmacology Case Paper
NR 546 Week 3 questions, answered
How many alternatives should the rationale consider?
One or two taken seriously beats four mentioned. Each alternative needs the argument for it as well as the reason against, which is real work, and a document with four of them usually gives none of them properly. Graders read the comparison section for depth rather than breadth, since a real prescriber weighs a small number of live options.
What if the case does not give me enough information?
Say what is missing and what you would ask, then reason from what you have. That is closer to practice than inventing a history, and it is usually marked as strength rather than as evasion. Inventing a comorbidity to justify a choice is the version that goes wrong, because a grader who supplied the case knows exactly what was not in it.
Does cost belong in the rationale?
Where your section allows it, yes, and it is often the most realistic factor available. Formulary position and out-of-pocket cost decide a great many prescriptions and saying so reads as practical. Keep it as one factor among several rather than the whole argument, and avoid quoting specific prices, which vary too much to state confidently.
Where can I find a free NR 546 Week 3 sample paper?
The escitalopram selection rationale is posted above as the NR 546 Week 3 sample, fully open. If your patient's factors point elsewhere, send us the case and a rationale defending that choice against its competitors can be drafted.
What should the NR 546 Week 3 rationale say about alternatives?
What would argue for each competitor and the specific patient factor that rules it out. The sample sets aside sertraline, bupropion and mirtazapine for reasons drawn from the patient.